NZ702297A - A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota - Google Patents

A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota

Info

Publication number
NZ702297A
NZ702297A NZ702297A NZ70229713A NZ702297A NZ 702297 A NZ702297 A NZ 702297A NZ 702297 A NZ702297 A NZ 702297A NZ 70229713 A NZ70229713 A NZ 70229713A NZ 702297 A NZ702297 A NZ 702297A
Authority
NZ
New Zealand
Prior art keywords
pharmaceutical composition
tryptophan
nicotinamide
nicotinic acid
intestinal microbiota
Prior art date
Application number
NZ702297A
Other languages
English (en)
Inventor
Georg Waetzig
Dirk Seegert
Original Assignee
Conaris Res Inst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Res Inst Ag filed Critical Conaris Res Inst Ag
Publication of NZ702297A publication Critical patent/NZ702297A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NZ702297A 2012-06-15 2013-06-14 A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota NZ702297A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012011890 2012-06-15
PCT/EP2013/062363 WO2013186355A1 (en) 2012-06-15 2013-06-14 A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota

Publications (1)

Publication Number Publication Date
NZ702297A true NZ702297A (en) 2016-11-25

Family

ID=47002494

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ702297A NZ702297A (en) 2012-06-15 2013-06-14 A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota

Country Status (32)

Country Link
US (2) US10426765B2 (show.php)
EP (2) EP3831379B1 (show.php)
JP (3) JP6855165B2 (show.php)
KR (2) KR20150021071A (show.php)
CN (2) CN108273064A (show.php)
AR (1) AR091465A1 (show.php)
AU (1) AU2013276451B2 (show.php)
BR (1) BR112014030835B1 (show.php)
CA (1) CA2876540C (show.php)
CY (1) CY1123999T1 (show.php)
DK (1) DK2861229T3 (show.php)
ES (1) ES2859758T3 (show.php)
HR (1) HRP20210090T1 (show.php)
HU (1) HUE053359T2 (show.php)
IL (1) IL236205B (show.php)
IN (1) IN2014DN10260A (show.php)
JO (1) JO3578B1 (show.php)
LT (1) LT2861229T (show.php)
MX (1) MX370795B (show.php)
NZ (1) NZ702297A (show.php)
PH (1) PH12014502744A1 (show.php)
PL (1) PL2861229T3 (show.php)
PT (1) PT2861229T (show.php)
RS (1) RS61288B1 (show.php)
RU (1) RU2657797C2 (show.php)
SA (1) SA113340643B1 (show.php)
SG (1) SG11201408251SA (show.php)
SI (1) SI2861229T1 (show.php)
SM (1) SMT202100248T1 (show.php)
TW (1) TWI624260B (show.php)
WO (1) WO2013186355A1 (show.php)
ZA (1) ZA201408922B (show.php)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN10260A (show.php) 2012-06-15 2015-08-07 Conaris Res Inst Ag
ES2978920T3 (es) 2013-06-05 2024-09-23 Univ British Columbia Compuestos antifibrogénicos, métodos y usos de los mismos
ES2785399T3 (es) * 2013-06-14 2020-10-06 Conaris Res Institute Ag Formulación de nicotinamida de liberación prolongada
EP2884282A1 (en) 2013-12-13 2015-06-17 CONARIS research institute AG Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency
JP6895752B2 (ja) * 2013-12-13 2021-06-30 コナリス リサーチ インスティチュート アーゲー ニコチン酸および／またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物
JP6554468B6 (ja) 2013-12-13 2019-09-11 コナリス リサーチ インスティチュート アーゲー ニコチンアミドと５−アミノサリチル酸との組合せを含有する、腸内微生物叢に有益な影響を及ぼすため、かつ／または胃腸の炎症を処置するための医薬組成物
EP3107553B1 (en) * 2014-02-18 2021-12-01 Universitätsklinikum Jena Methods and compositions for intestinal microenvironment transfer
CN106413680A (zh) * 2014-05-12 2017-02-15 荷兰联合利华有限公司 用于诱导抗微生物肽生成的烟酰胺
CN105287561A (zh) * 2015-11-25 2016-02-03 上海交通大学医学院附属瑞金医院 一种治疗溃疡性结肠炎的药物组合物
BR112018071074B1 (pt) * 2016-04-14 2023-10-03 Chromadex Inc Fórmula infantil
RU2738114C2 (ru) * 2016-04-19 2020-12-08 Конарис Рисёрч Инститьют Аг Пероральные фармацевтические композиции никотинамида
KR102381586B1 (ko) 2016-04-19 2022-04-04 훼링 비.브이. 메살라진의 경구용 약제학적 조성물
CN109718234A (zh) * 2017-10-31 2019-05-07 中国农业大学 L-色氨酸在缓解肠道炎症反应和屏障功能紊乱中的应用
CN108935981A (zh) * 2018-06-05 2018-12-07 西北农林科技大学 围产期奶山羊添加烟酰胺对羔羊糖脂代谢的影响及其机制
WO2020166527A1 (ja) * 2019-02-12 2020-08-20 めぐみ 田中 乳幼児用飲食品、乳幼児の腸内環境の改善方法、及び乳幼児の免疫力の増強方法
CN113573777A (zh) 2019-03-28 2021-10-29 国立大学法人东北大学 癌的预防或治疗剂
CN113398130A (zh) * 2020-03-16 2021-09-17 广州市妇女儿童医疗中心（广州市妇幼保健院、广州市儿童医院、广州市妇婴医院、广州市妇幼保健计划生育服务中心） 烟酰胺用于预防和治疗胃肠道功能紊乱的用途
CN116635025A (zh) * 2020-11-27 2023-08-22 康纳里斯研究院股份公司 用于缩短covid-19和其他病毒感染患者的症状消退时间的烟酰胺、烟酰胺前体和烟酰胺代谢物及其组合物
WO2022112489A1 (en) * 2020-11-27 2022-06-02 Conaris Research Institute Ag Nicotinamide, nicotinamide precursors and nicotinamide metabolites and compositions thereof for reducing the time to resolution of symptoms in patients with covid-19 and other viral infections
TW202308605A (zh) * 2021-07-19 2023-03-01 日商明治控股股份有限公司 用於炎症性腸疾病之預防或改善之組合物、以及用於腸內細菌叢調節之組合物
WO2023187003A1 (en) * 2022-03-30 2023-10-05 Conaris Research Institute Ag Composition comprising nicotinamide, nicotinamide precursors, nicotinamide metabolites or combinations thereof for preventing or reducing one or more post-acute symptoms of infectious diseases
KR102789810B1 (ko) 2023-02-06 2025-03-31 한림대학교 산학협력단 아토피 피부염 진단용 바이오마커
CN117837697A (zh) * 2023-12-22 2024-04-09 汕头大学 一种烟酰胺的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
DE19524928A1 (de) * 1995-07-08 1997-01-09 Basf Ag Verfahren zur Rektifikation von Gemischen hochsiedender luft- und/oder temperaturempfindlicher Substanzen, die eine hohe Trennleistung erfordern, im Feinvakuum, sowie für dieses Verfahren geeignete Kolonnen
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5736532A (en) * 1996-02-14 1998-04-07 Furda; Ivan Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
JP2002533415A (ja) * 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびニコチン酸誘導体の組み合わせ
US6713057B1 (en) 1999-02-24 2004-03-30 The Johns Hopkins University Compositions and methods for modulating serum cholesterol
GB0015242D0 (en) 2000-06-22 2000-08-16 Nycomed Amersham Plc Stabiliser for radiopharmaceuticals
WO2002011725A1 (en) 2000-08-08 2002-02-14 Shionogi & Co., Ltd. Inflammatory cytokine production inhibitors
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2005072113A2 (en) 2004-01-20 2005-08-11 Harty Richard F Compositions and methods of treatment for inflammatory diseases
US20060264409A1 (en) 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
CA2565993C (en) 2004-05-27 2011-08-16 Antibe Therapeutics Inc. Salt of 4-or 5- aminosalicylic acid
CA2581775A1 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule - formulations
EP1920770A4 (en) * 2005-07-01 2010-09-29 Ajinomoto Kk THERAPEUTIC AGENT AGAINST INFLAMMATORY DISEASE AND TNF ALPHA PRODUCTION DISEASE
EP2026651B1 (en) * 2006-03-08 2013-04-17 Cortria Corporation Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
ITMI20061932A1 (it) 2006-10-09 2008-04-10 Carlo Ghisalberti Complessi a trasferimento di carica per uso medicale
EP1935422A1 (en) * 2006-12-20 2008-06-25 PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG Pharmaceutical composition comprising nicotinamide or nicotinic acid
US20090104171A1 (en) * 2007-10-19 2009-04-23 Pardee Joel D Metabolic Enhancement Therapy
WO2009131537A1 (en) * 2008-04-25 2009-10-29 Karolinska Institutet Innovations Ab New therapy of treatment of the irritable bowel syndrome.
JP2011521915A (ja) * 2008-05-20 2011-07-28 セレニス セラピューティクス エス．エー． ナイアシン及びｎｓａｉｄ併用療法
WO2009149058A2 (en) 2008-06-02 2009-12-10 Dr. Reddy's Laboratories Ltd. Modified release niacin formulations
CA2739465C (en) 2008-10-03 2017-01-31 Dr. Falk Pharma Gmbh Compositions and methods for the treatment of bowel diseases with granulated mesalamine
JP2011121889A (ja) 2009-12-09 2011-06-23 En Otsuka Pharmaceutical Co Ltd 炎症性腸疾患用アミノ酸組成物
JP2012102054A (ja) * 2010-11-11 2012-05-31 Kyodo Milk Industry Co Ltd 腸内ポリアミン増強剤
WO2012090224A1 (en) 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug
IN2014DN10260A (show.php) 2012-06-15 2015-08-07 Conaris Res Inst Ag
ES2785399T3 (es) 2013-06-14 2020-10-06 Conaris Res Institute Ag Formulación de nicotinamida de liberación prolongada
RU2738114C2 (ru) 2016-04-19 2020-12-08 Конарис Рисёрч Инститьют Аг Пероральные фармацевтические композиции никотинамида
WO2022112489A1 (en) * 2020-11-27 2022-06-02 Conaris Research Institute Ag Nicotinamide, nicotinamide precursors and nicotinamide metabolites and compositions thereof for reducing the time to resolution of symptoms in patients with covid-19 and other viral infections

Also Published As

Publication number Publication date
JP6855165B2 (ja) 2021-04-07
IN2014DN10260A (show.php) 2015-08-07
BR112014030835B1 (pt) 2022-01-11
SG11201408251SA (en) 2015-01-29
PL2861229T3 (pl) 2021-08-09
CY1123999T1 (el) 2022-05-27
PH12014502744A1 (en) 2015-02-02
HRP20210090T1 (hr) 2021-03-05
US20150126462A1 (en) 2015-05-07
PT2861229T (pt) 2021-01-05
EP2861229B1 (en) 2020-12-23
ES2859758T3 (es) 2021-10-04
AU2013276451B2 (en) 2018-03-29
CN104363907A (zh) 2015-02-18
AU2013276451A1 (en) 2015-01-15
EP2861229A1 (en) 2015-04-22
RS61288B1 (sr) 2021-02-26
CN108273064A (zh) 2018-07-13
RU2657797C2 (ru) 2018-06-15
MX2014015217A (es) 2015-03-05
SI2861229T1 (sl) 2021-03-31
IL236205A0 (en) 2015-01-29
DK2861229T3 (da) 2021-01-18
SMT202100248T1 (it) 2021-05-07
EP3831379B1 (en) 2025-09-10
US10426765B2 (en) 2019-10-01
AR091465A1 (es) 2015-02-04
ZA201408922B (en) 2016-10-26
RU2014148239A (ru) 2016-08-10
LT2861229T (lt) 2021-01-25
EP3831379A1 (en) 2021-06-09
SA113340643B1 (ar) 2019-10-06
TWI624260B (zh) 2018-05-21
MX370795B (es) 2020-01-08
CA2876540A1 (en) 2013-12-19
HUE053359T2 (hu) 2021-06-28
JP2015519388A (ja) 2015-07-09
HK1204972A1 (en) 2015-12-11
JP2019069972A (ja) 2019-05-09
CA2876540C (en) 2022-11-29
JP2022017332A (ja) 2022-01-25
KR102211832B1 (ko) 2021-02-02
JO3578B1 (ar) 2020-07-05
TW201400116A (zh) 2014-01-01
WO2013186355A1 (en) 2013-12-19
KR20150021071A (ko) 2015-02-27
US20200009124A1 (en) 2020-01-09
BR112014030835A2 (pt) 2017-06-27
KR20200011619A (ko) 2020-02-03
IL236205B (en) 2020-02-27

Similar Documents

Publication Publication Date Title
NZ702297A (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
WO2010035219A3 (en) Pyrazolo pyridine derivatives as nadph oxidase inhibitors
DK2007429T3 (da) Oralt præparat med gavnlige cardiovaskulære virkninger indeholdende berberin
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
WO2010123591A3 (en) Small molecule inhibitors of nads, namnat, and nmnat
WO2012019426A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
PH12012502568A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
PH12014501134A1 (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
WO2012019430A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
JO2761B1 (en) Derivatives of alcohols 1-phenyl-2-pyridinealkyl as inhibitors
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
GEP20156372B (en) Pyridazinone compounds and their use as daao inhibitors
NZ627942A (en) Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
BR112012020742A2 (pt) derivados de pirazolo piperidina como inibidores de nadph oxidase.
PE20141410A1 (es) 3,4 dihidro 1h[1,8] naftiridinonas antibacterianas sustituidas con ciclopenta [c] pirrol
MX350810B (es) Derivados de los nucleosidos sustituidos en 4 '-azido, 3 '-fluoro como inhibidores de la replicacion del rna del vhc.
MX2013006174A (es) Preparacion que comprende insulina, nicotinamida y un aminoacido.
WO2011042860A3 (en) New derivatives of thieno[2,3-b]pyridine and 5,6,7,8-tetrahydrothieno[2,3-b]quinoline in particular useful in the treatment of malaria
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
MA32406B1 (fr) Composés contenant de l'azote tricyclique et utilisation de ceux-ci comme antibactériens
MX2015001143A (es) Composiciones herbicidas que comprenden acido 4-amino-3-cloro-5-fluoro-6- (4-cloro-2-fluoro-3-metoxifenilo) piridin-2-carboxilico.
NZ701882A (en) Process for the selective reduction of bile acids, their salts or derivatives, in a biphasic system
EP2663646A2 (en) Method for the preparation of nicotinic acid
GEP20125680B (en) Carbonic and sulphuric acid salts of 3-(2,2,2-trimethylhydra-zinium) ropionate esters and their use for 3-(2,2,2-rimethyl- hydrazinium) propionate dihydrate preparation
EP4461359A3 (en) Composition for external skin use for inflammatory diseases

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2018 BY CPA GLOBAL

Effective date: 20170428

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2019 BY PAVIS GMBH

Effective date: 20180612

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2020 BY PAVIS GMBH

Effective date: 20190607

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2021 BY PAVIS GMBH

Effective date: 20200605

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2022 BY PAVIS PAYMENTS GMBH

Effective date: 20210603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2023 BY PAVIS PAYMENT GMBH

Effective date: 20220602

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2024 BY PAVIS PAYMENTS GMBH

Effective date: 20230601

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2025 BY PAVIS PAYMENT GMBH

Effective date: 20240603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2026 BY PAVIS PAYMENTS GMBH

Effective date: 20250530